Logotype for Dexcom Inc

Dexcom (DXCM) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dexcom Inc

Q3 2026 earnings summary

30 Oct, 2026

Executive summary

  • Q3 revenue was $1,344.5M, up 11% YoY on reported and organic bases; U.S. growth was 14% and international growth was 5%.

  • Gross profit increased 18% and operating income increased 35% on a GAAP basis; GAAP net income declined 3%, while non-GAAP diluted EPS reached a quarterly record $0.73.

  • Nine-month revenue reached $3,844.8M, up 13% YoY; operating income rose 53% and net income rose 27%.

  • Growth reflected higher sensor volume and customer expansion, alongside U.S. share gains and near-record global new patient starts.

Financial highlights

  • Revenue was $1,344.5M vs. $1,209.3M in Q3 2025; U.S. revenue was $969.8M, up 14%, and international revenue was $374.7M, up 5%.

  • GAAP gross profit was $864.4M vs. $731.4M, with gross margin of 64.3% vs. 60.5%; non-GAAP gross profit was $875.3M and margin was 65.1% vs. 61.3%.

  • GAAP operating income was $327.2M vs. $242.5M; non-GAAP operating income was $339.5M vs. $272.9M.

  • GAAP net income was $275.1M vs. $283.8M and diluted EPS was $0.72 vs. $0.70; non-GAAP net income was $275.0M vs. $242.5M and EPS was $0.73 vs. $0.61.

  • Nine-month gross profit was $2,444.7M, operating income $900.8M, and net income $723.7M; diluted EPS was $1.87 vs. $1.42.

Outlook and guidance

  • FY2026 revenue guidance increased to $5.20B–$5.25B, representing 12%–13% growth; the midpoint reflects Q3 outperformance partly offset by ~$5M of incremental FX headwinds and implies 10% Q4 growth.

  • FY2026 non-GAAP gross margin guidance remains ~64%; operating margin guidance increased to ~24% and Adjusted EBITDA margin guidance to ~32%.

  • Ireland startup costs are expected to weigh on Q4 and early 2027; G7 15 Day adoption, manufacturing efficiencies and the absence of Ireland expansion costs are expected to support later margin progression.

  • Medicare coverage for type 2 non-insulin users is expected to be decided this year, with coverage currently anticipated to take effect mid-2027; G8 remains targeted for late 2027 or early 2028, subject to regulatory review.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Dexcom